AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
Completed
- Conditions
- GERD
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00634023
- Locations
- 🇨🇦
Research Site, Woodstock, Ontario, Canada
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Phase 1
Completed
- Conditions
- Neoplasm Metastasis
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00633269
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00633412
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00633672
Reflux Esophagitis Phase III Study (Initial Treatment)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 602
- Registration Number
- NCT00633932
- Locations
- 🇯🇵
Research Site, Tottori, Japan
Reflux Esophagitis Phase III Study (Maintenance Treatment)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00634114
- Locations
- 🇯🇵
Research Site, Tottori, Japan
IRESSA™ (Gefitinib) in Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00632723
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
Phase 4
Completed
- Conditions
- Type IIa and IIb Hypercholesterolaemia
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 668
- Registration Number
- NCT00631189
- Locations
- 🇫🇷
Research Site, Yffiniac, France
Prevention of Gastric Ulcers
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 504
- Registration Number
- NCT00629512
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00629564
© Copyright 2025. All Rights Reserved by MedPath